showed that mRNA encoding the full-length cytoplasmic tyrosine kinase domain of the receptor was only expressed in a subset of favourable tumours. These data show that favourable neuroblastomas may express the full trkC receptor while advanced tumours, in particular MYCN-amplified neuroblastoma, seem to either express no trkC or truncated trkC receptors of as yet unknown biological function. These data are suggestive of a role for trkC and its preferred ligand neutotrophin-3, NT-3, in neuroblastoma differentiation and/or regression.
Neuroblastoma (NB) is a complex childhood tumour derived from sympathoadrenal progenitors of the neural crest with a broad clinical spectrum, including spontaneous regression of widespread disease and poor outcome despite highly intensive multimodal therapy. NB tumours are classified into localised (stage 1 and 2), regional (stage 3) and metastatic (stage 4) with an additional subset of widespread infant tumours (stage 4S), which often show spontaneous regression and/or differentiation . Age at diagnosis is an important factor related to prognosis, the majority of neuroblastomas occurring under 1-2 years of age are of stages 1, 2 or 4S with a favourable clinical outcome. Patients over 1-2 years of age often present advanced tumours, and in this group survival rates have not improved significantly during recent years despite increasingly aggressive therapy. The clinical heterogeneity of NB has stimulated an intensive search for biological markers correlated with prognosis, in order to allow, at an early stage the assessment of the individual patient as having favourable or poor prognosis respectively. Genomic amplification of the N-myc oncogene (MYCN), is correlated with advanced stage and unfavourable outcome (Brodeur et al., 1984; Schwab et al., 1983; Seeger et al., 1985) . Genetic aberrations found in NB include other structural chromosomal abnormalities, in particular deletions involving the short arm of chromosome 1 (Brodeur et al., 1977) . Recent data indicate that chromosome lp harbours one or several tumour-suppressor genes that may be specific for the development of unfavourable NB (Caron et al., 1995; Martinsson et al., 1995; White et al., 1995) .
Introduction of a functional trkA cDNA into NB cell lines allowed differentiation after NGF treatment indicating that loss of functional NGF receptor expression may play an important role in the behaviour of advanced NB (Matsushima and Bogenmann, 1993; Poluha et al., 1995) . In culture of primary NB tumours expressing trkA, NGF induced terminal differentiation, whereas NGF deprivation resulted in cell death (Nakagawara et al., 1993) . In agreement with this, trkA expression has been found to be associated with young age at diagnosis and non-advanced stages of NB tumours.
Simultaneous expression of trkA and p75LNGFR mRNA has been shown to define a favourable subset of NB tumours which either differentiate or regress spontaneously and/or respond to therapy (Kogner et al., 1993; Nakagawara et al., 1993) . Analysis of trkA and p75 mRNA, combined with analysis of DNA content in tumour cells, may predict clinical outcome in most children with NB (Kogner et al., 1994) .
The role of NGF and its receptors in NB has raised interest in the possible participation of other members of the neurotrophin family. Brain-derived neurotrophic factor (BDNF) (Barde et al., 1982; Leibrock et al., 1989) (Nakagawara et al., 1994) . In this study we have investigated the mRNA expression profile of the third member of the neurotrophin receptor tyrosine kinase family, trkC, a receptor for neurotrophin-3 (NT-3) (Lamballe et al., 1991) which is involved in the survival of subpopulations of neural crest and placodederived sensory neurons (Ernfors et al., 1994 (Shelton et al., 1995) which was identical to that of our clone in the transmembrane region. Initial Northern blot analysis showed that levels of trkC mRNA were below the detection limit in most samples. However, one favourable stage 4S tumour, showed significant trkC mRNA expression (no. 1, Figure la) . This prompted us to develop a RNAse protection assay for human trkC mRNA to achieve higher sensitivity. (Figure 2 ). In the neuroblastoma cell line SH-SY5Y, low levels of trkC mRNA could be detected ( Figure 2 ). As expected, trkC mRNA was highly expressed in normal brain tissue (Figure lb) . A relapsing stage 1 tumour showed a relatively low level of trkC expression (no. 24, Figure 2 the human trkC receptor (Shelton et al., 1995 (Hoehner et al., 1995) . It was found that the more differentiated tumour cells stained most intensely for trkC but there was no significant correlation with tumour stage or patient prognosis.
Combining our own present and previous results (Kogner et al., 1993) with those from other groups (Borello et al., 1993; Kaplan et al., 1993; Matsumoto et al., 1995; Nakagawara et al., 1994; Suzuki et al., 1993) a specific pattern of neurotrophin receptor expression in various neuroblastoma tumours emerges. Favourable neuroblastoma tumours express trkA together with p75LNGFR and sometimes full-length trkC, but only truncated trkB. On the other hand, aggressive NB and MYCN-amplified tumours in particular, lack trkA and p75LNGFR expression while they may coexpress full-length trkB with its primary ligand BDNF together with either no trkC or truncated trkC (Table II) . The functional significance of these patterns of expression of neurotrophin receptors in NB remains to be fully defined. It was recently suggested that neurotrophic factors could be provided to differentiating tumour cells by infiltrating normal Schwann cells that can often be found in maturing NB (Ambros and Ambros, 1995) . NGF and its receptors are suggested to play a part in tumour differentiation and regression or apoptosis (Matsushima and Bogenmann, 1993; Nakagawara et al., 1993; Poluha et al., 1995) while the trkB-BDNF autocrine loop has been proposed to support tumour survival and invasiveness (Kaplan et al., 1993; Matsumoto et al., 1995; Nakagawara et al., 1994 
